Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AAVLP-HPV Vaccine in Healthy Adults
NCT03929172Phase 1Completed
- Sponsor
- 2A Pharma
- Start
- Feb 2019
- Primary completion
- May 2020
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human papillomavirus infection comparing AAVLP-HPV Vaccine Arm with Placebo Arm (2 arms). Primary endpoints: Percentage of Subjects Reporting Solicited Local Symptoms, Percentage of Subjects Reporting Solicited General Symptoms and 8 more. Started Feb 2019; status: completed.
02
Drugs
AAVLP-HPV
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03929172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929172.